Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)


A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation




This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called Glioblastoma Multiforme (GBM). ICT-107 is an immunotherapy in which the patient`s immune response will be stimulated to kill the tumor cells. Patients must be newly diagnosed with GBM and not yet received chemoradiation. Some of the patient`s white blood cells (WBC) will be removed and cultured in a laboratory with purified antigens, similar to those on GBM cells. The patient`s own WBC/DC that have been exposed to the tumor antigens will then be given back to the patient as a vaccine over several months. The goal is for the ICT-107 vaccine to stimulate the patient`s immune response to kill the remaining GBM tumor cells after surgery and chemotherapy.

Study Status: Active, not recruiting


Condition Intervention Phase
Glioblastoma Multiforme Biological: ICT-107
Biological: Placebo DC
Phase 2

Verified by ImmunoCellular Therapeutics, Ltd. October, 2012

Sponsored by: ImmunoCellular Therapeutics, Ltd.
Information provided by: ImmunoCellular Therapeutics, Ltd. identifier: NCT01280552

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Cleveland Clinic Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site